In a phase IIIb trial conducted at 44 centers worldwide between April 2009 and November 2010 , otherwise healthy women aged 14-50 years requesting contraception were randomized to daily oral administration of E ( 2 ) V/DNG ( n = 253 ) or EE/LNG ( n = 254 ) for three 28-daycycles .